Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation has published another study touting the effectiveness of its anti-inflammatory ALT-100 monoclonal antibody (mAb)
Related